

## PRESS RELEASE

Lyon, June 10, 2026

---

# ADOCIA Confirms its Eligibility for the PEA-PME Scheme

6:00 pm CEST - Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, confirms that it meets the eligibility criteria for its shares to be held in a PEA-PME account, set forth in Article L.221-32-2 of the French Monetary and Financial Code.

Consequently, investment in Adocia shares can be made through PEA-PME savings accounts. This scheme is specially designed to encourage investment in small and medium-sized companies, offering tax benefits notably an income tax exemption on gains realized, provided no withdrawals are made during the first 5 years.

## About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® for the stabilization and enhancement of peptide formulations and combinations; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoXLong™, a long-acting peptide platform.

Adocia holds more than 25 patent families. Based in Lyon, the Company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

# Contact

## Adocia

Olivier Soula

CEO

[contactinvestisseurs@adocia.com](mailto:contactinvestisseurs@adocia.com)

+33 (0)4 72 610 610



[www.adocia.com](http://www.adocia.com)



European **Rising Tech**  
LABEL



**ADOCIA**

innovative medicine  
for everyone, everywhere



## Maarc

Adocia Press & Investor Relations

Bruno Arabian

Yasmine Duval

Thomas Rolnik

[adocia-actionnaires@maarc.fr](mailto:adocia-actionnaires@maarc.fr)

+ 33 (0)6 87 88 47 26

## Disclaimer

*This press release contains certain forward-looking statements concerning Adocia, its business and the markets in which Adocia operates. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2026, available at [www.adocia.com](http://www.adocia.com). Those risks include in particular uncertainties inherent in Adocia's short- or medium-term working capital requirements, the Company's current financing horizon being limited to the beginning of Q2 2027. The Company is also subject to other risks and uncertainties relating to research and development,*

*future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds.*

*The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia at this time. The occurrence of all or part of such risks could cause the actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or a solicitation of an offer to buy or subscribe for, Adocia shares in any country.*